Nuvation Bio (NUVB) Net Cash Flow (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Net Cash Flow of -$38.5 million for Q1 2026, down 418.29% year-over-year from $12.1 million in Q1 2025, and down 158.89% quarter-over-quarter from $65.4 million in Q4 2025.
Nuvation Bio (NUVB) Net Cash Flow (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Net Cash Flow for 7 consecutive years, with -$38.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 418.29% year-over-year to -$38.5 million; the TTM figure through Mar 2026 stood at $78.0 million (up 506.41% YoY), while the FY2025 annual figure was $128.6 million, up 1843.16% from the prior year.
- Net Cash Flow slipped to -$38.5 million in Q1 2026 per NUVB's latest filing, from $65.4 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $200.1 million in Q2 2025 and bottomed at -$149.0 million in Q3 2025.
- Historically, Net Cash Flow has averaged -$414588.2 across 5 years, with a median of -$3.5 million in 2024.
- On a YoY basis, Net Cash Flow climbed as much as 66146.53% in 2025 and fell as far as 4149.07% in 2025.
- Nuvation Bio's Net Cash Flow stood at -$37.6 million in 2022, then soared by 148.56% to $18.3 million in 2023, then slumped by 74.96% to $4.6 million in 2024, then soared by 1331.49% to $65.4 million in 2025, then sank by 158.89% to -$38.5 million in 2026.
- Business Quant data shows NUVB's Net Cash Flow at -$38.5 million in Q1 2026, $65.4 million in Q4 2025, and -$149.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | 133.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 133.52 Mn |
| Jun 30, 2026 | 133.52 Mn |
| Mar 31, 2026 | -38.52 Mn |
| Mar 31, 2026 | -38.52 Mn |
| Dec 31, 2025 | 65.42 Mn |
| Dec 31, 2025 | 65.42 Mn |
| Sep 30, 2025 | -149.02 Mn |
| Sep 30, 2025 | -149.02 Mn |
| Jun 30, 2025 | 200.12 Mn |
| Jun 30, 2025 | 200.12 Mn |
| Mar 31, 2025 | 12.10 Mn |
| Mar 31, 2025 | 12.10 Mn |
| Dec 31, 2024 | 4.57 Mn |
| Dec 31, 2024 | 4.57 Mn |
| Sep 30, 2024 | -3.51 Mn |
| Sep 30, 2024 | -3.51 Mn |
| Jun 30, 2024 | -303,000.00 |
| Jun 30, 2024 | -303,000.00 |
| Mar 31, 2024 | -8.14 Mn |
| Mar 31, 2024 | -8.14 Mn |